Turkish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Sayfa 1 itibaren 19 Sonuçlar
Somatostatin-dopamine chimeric analogs
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
The present invention is drawn to somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use.
Dopamine is a catecholamine neurotransmitter that has been implicated in the pathogenesis of both Parkinson disease and schizophrenia. Dopamine and
Somatostatin-dopamine chimeric analogs
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
The present invention is drawn to somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use.
Dopamine is a catecholamine neurotransmitter that has been implicated in the pathogenesis of both Parkinson disease and schizophrenia. Dopamine and
Somatostatin-dopamine chimeric analogs
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The present invention relates to novel somatostatin-dopamine chimeric analogs having improved activity and uses thereof in, inter alia, the inhibition, prevention, and/or treatment of neuroendocrine tumors, neoplasia, acromegaly, Cushing's disease/syndrome and/or other
Somatostatin-dopamine chimeric analogs
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The present invention relates to novel somatostatin-dopamine chimeric analogs having improved activity and uses thereof in, inter alia, the inhibition, prevention, and/or treatment of neuroendocrine tumors, neoplasia, acromegaly, Cushing's disease/syndrome and/or other
Somatostatin-dopamine chimeric analogs
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The present invention relates to novel somatostatin-dopamine chimeric analogs having improved activity and uses thereof in, inter alia, the inhibition, prevention, and/or treatment of neuroendocrine tumors, neoplasia, acromegaly, Cushing's disease/syndrome and/or other
Pancreatic cancer therapy and diagnosis
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a national phase application under 35 U.S.C. .sctn. 371 of International Application No. PCT/EP2015/058380 filed 17 Apr. 2015, which claims priority to European Patent Application No. 14165053.1 filed 17 Apr. 2014. The entire contents of
Method and compositions for treating tumors having high tyrosinase activity
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The present invention is directed to methods and compositions for treating tumors and other metastatic diseases exhibiting high tyrosinase and saccharide enzyme activity. The invention is further directed to methods and compositions for treating tumors having high tyrosinase
Method and compositions for treating tumors having high tyrosinase activity
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The present invention is directed to methods and compositions for treating tumors and other metastatic diseases exhibiting high tyrosinase and .beta.-glucuronidase activity. The invention is further directed to methods and compositions for treating tumors having high
Combination therapy for the treatment of cancer
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE DISCLOSURE
The disclosure relates to methods and compositions for the treatment of cancer and particularly to methods and compositions for the treatment of cancer with a dopamine receptor antagonist and chemotherapeutic agent.
BACKGROUND OF THE DISCLOSURE
Increasing evidence suggests
Combination therapy for the treatment of cancer
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE DISCLOSURE
The disclosure relates to methods and compositions for the treatment of cancer and particularly to methods and compositions for the treatment of cancer with a dopamine receptor antagonist and chemotherapeutic agent.
BACKGROUND OF THE DISCLOSURE
Increasing evidence suggests
Unifying mechanism and methods to prevent cancer and neurodegenerative diseases
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
Cancer is a disease that begins with mutation of critical genes: oncogenes and tumor suppressor genes. Mutation of critical genes allows for a cancer cell to evolve and ultimately results in pathogenic replication (a loss of normal regulatory control leading to excessive
Methods for identifying and validating selective anti-cancer stem cell agents
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE DISCLOSURE
The disclosure relates to methods for the prognosis or treatment of cancer and screening methods and particularly to methods for the prognosis or treatment of cancer that target dopamine receptors and screening methods for the identification and validation of agents that
Imipridones for gliomas
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
ONC201 (7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo [1,2-a]pyrido [3,4-e]pyrimidin-5(1H)-one) is the founding member of a class of anti-cancer compounds called imipridones that is in Phase II clinical trials in multiple advanced cancers. Since the discovery
Imipridones for gliomas
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
BACKGROUND OF THE INVENTION
ONC201 (7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo [1,2-a]pyrido [3,4-e]pyrimidin-5(1H)-one) is the founding member of a class of anti-cancer compounds called imipridones that is in Phase II clinical trials in multiple advanced cancers. Since the discovery
Thiazole derivatives
Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
FIELD OF THE INVENTION
The subject invention relates to thiazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present
Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı
- 55 dilde çalışır
- Bilim destekli bitkisel kürler
- Görüntüye göre bitki tanıma
- Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
- Aramanızla ilgili bilimsel yayınları okuyun
- Şifalı bitkileri etkilerine göre arayın
- İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın
Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır
